Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Drug Approval-Patent Linkage Systems in the US and Canada

미국과 캐나다의 의약품 허가-특허 연계제도

  • Published : 2008.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Drug approval-patent linkage is the practice of linking drug marketing approval to the patent status of the originator's product and not allowing the grant of marketing approval to any third party prior to the expiration of the patent term unless by consent of the patent owner. Article 18.9.5 of Korea-US Free Trade Agreement requires that Korea introduce the linkage system in drug marketing approval. However, Korea is unfamiliar with the linkage system. In addition, there have been lots of arguments over the impacts of this system on Korean pharmaceutical industry and pharmaceutical market in the future. This report investigated the linkage systems of the US and Canada. The US and Canada have implemented drug approval-patent linkage system since 1984 and 1993, respectively. Both countries have patent lists for drug approvalpatent linkage on which originators are required to list patents on substance, product, and use of their drugs. Generic or follow-on drug applicants must contain a certification regarding each patent listed that relates to the referenced drug. If the patent holder files suit for patent infringement within 45 days of notice of application, drug approval is not allowed for several months - 30 months in the US and 24 months in Canada. Both countries have amended their systems after having experienced unexpected results such as listing improper and additional patents, multiple patent litigations and delayed generic entries. After reviewing the US and Canada's experiences, we suggested three principles needed in implementing the system: protecting patent holder's right; promoting generic drug development and marketing; monitoring the process and the effect of the system.

Keywords

References

  1. US FDA, Guidance for industry: listed drugs, 30-month stays, and approval of ANDAs and 505(b)(2) applications under Hatch-Waxman, as amended by the Medicare Prescription Drugs, Improvement and Modernization Act of 2003 (2004)
  2. 21 CFR 314.95, Notice of certification of invalidity or noninfringement of a patent
  3. FTC, Generic drug entry prior to patent expiration (2002)
  4. R. G. Frank and E. Seiguer, Generic drug competition in the US. Business Briefing, Pharmatech (2003)
  5. R. J. Strongin, Hatch-Waxman, generics, and patents: balancing prescription drug innovation, competition, and affordability, National Health Policy Forum (2002)
  6. W. H. Schacht and J. R. Thomas, The Hatch-Waxman act: legislative changes in the 108th congress affecting pharmaceutical patents, Congressional Research Service (2004)
  7. 21 CFR 314.53, Submission of patent information
  8. J. R. Thomas, Authorized generic pharmaceuticals: effects on innovation. Congressional Research Service (2006)
  9. Library of Parliament in Canada, The patented medicines (notice of compliance) regulations 2006 (2007)
  10. Office of Patented Medicines and Liaison, Therapeutic products directorate statistical report (2006)
  11. Health Canada, Therapeutic products directorate statistical report (2007)
  12. Canada Patent Act, Regulations amending the patented medicines (notice of compliance) regulations (2006)
  13. C. McCourt, E. McMahon and I. VanderElst, Amendments to the patented medicines (notice of compliance) regulations and the data protection regulations are now in force, Torys LLP, October 10 (2006)